RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+46.61%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.86B
AUM Growth
+$7.86B
(+23%)
Cap. Flow
+$280M
Cap. Flow
% of AUM
3.56%
Top 10 Holdings %
Top 10 Hldgs %
51.1%
Holding
83
New
21
Increased
18
Reduced
5
Closed
7
Top Buys
| 1 |
Edgewise Therapeutics
EWTX
|
$163M |
| 2 |
Dyne Therapeutics
DYN
|
$141M |
| 3 |
Evolent Health
EVH
|
$105M |
| 4 |
LENZ
LENZ Therapeutics
LENZ
|
$93.3M |
| 5 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$71M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$704M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$164M |
| 3 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
$94M |
| 4 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$93.6M |
| 5 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$73.2M |
Sector Composition
| 1 | Healthcare | 99.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BOLD
51
Boundless Bio
BOLD
$25.7M
| $31.1M | 0.4% |
+2,180,631
| New | +$31.1M |
|
52
MacroGenics
MGNX
$121M
| $30.6M | 0.39% |
2,082,021
-1,971,056
| -49% | -$29M |
|
53
Tenaya Therapeutics
TNYA
$192M
| $30.1M | 0.38% |
5,755,050
+247,703
| +4% | +$1.3M |
|
|
CYBN
54
Cybin
CYBN
$142M
| $24M | 0.31% |
+58,139,535
| New | +$24M |
|
55
Alto Neuroscience
ANRO
$97.7M
| $21.3M | 0.27% |
+1,385,491
| New | +$21.3M |
|
56
CervoMed
CRVO
$93M
| $20.1M | 0.26% |
+861,573
| New | +$20.1M |
|
|
VXRT
57
DELISTED
Vaxart
VXRT
| $20M | 0.25% |
+15,384,615
| New | +$20M |
|
|
BCYC
58
Bicycle Therapeutics
BCYC
$492M
| $19.9M | 0.25% |
800,000
| – | – |
|
59
EyePoint Pharmaceuticals
EYPT
$827M
| $19.4M | 0.25% |
+938,591
| New | +$19.4M |
|
|
THRD
60
DELISTED
Third Harmonic Bio
THRD
| $19.2M | 0.24% |
2,033,056
| – | – |
|
61
Pliant Therapeutics
PLRX
$105M
| $19.1M | 0.24% |
1,281,000
| – | – |
|
62
Sera Prognostics
SERA
$129M
| $18.4M | 0.23% |
+2,024,221
| New | +$18.4M |
|
63
Metagenomi
MGX
$67.2M
| $18.4M | 0.23% |
+1,744,415
| New | +$18.4M |
|
64
Immatics
IMTX
$662M
| $18.4M | 0.23% |
+1,750,000
| New | +$18.4M |
|
65
AN2 Therapeutics
ANTX
$35.3M
| $18M | 0.23% |
5,551,295
| – | – |
|
|
RGLS
66
DELISTED
Regulus Therapeutics
RGLS
| $18M | 0.23% |
+6,250,000
| New | +$18M |
|
67
Black Diamond Therapeutics
BDTX
$164M
| $17.9M | 0.23% |
3,525,754
| – | – |
|
68
Adicet Bio
ACET
$60.8M
| $17.7M | 0.23% |
+7,541,000
| New | +$17.7M |
|
69
Arvinas
ARVN
$580M
| $17.4M | 0.22% |
421,348
| – | – |
|
70
Lexeo Therapeutics
LXEO
$266M
| $10.4M | 0.13% |
+660,938
| New | +$10.4M |
|
|
CMRX
71
DELISTED
Chimerix, Inc.
CMRX
| $9.33M | 0.12% |
8,800,000
| – | – |
|
|
IGMS
72
DELISTED
IGM Biosciences
IGMS
| $9.05M | 0.12% |
937,500
| – | – |
|
|
CMPS
73
Compass Pathways
CMPS
$452M
| $6.58M | 0.08% |
791,359
-494,641
| -38% | -$4.12M |
|
74
CureVac
CVAC
$1.21B
| $5.96M | 0.08% |
1,965,707
-778,563
| -28% | -$2.36M |
|
75
Unicycive Therapeutics
UNCY
$75.8M
| $4.79M | 0.06% |
3,470,688
| – | – |
|